Relmada Therapeutics (RLMD) Non-Current Assets (2013 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Non-Current Assets of $19500.0 for Q1 2026, down 11.26% year-over-year from $21975.0 in Q1 2025, and little changed quarter-over-quarter from $19500.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Non-Current Assets (2013 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Non-Current Assets for 14 consecutive years, with $19500.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 11.26% year-over-year to $19500.0; the TTM figure through Mar 2026 stood at $82950.0 (down 30.61% YoY), while the FY2025 annual figure was $19500.0, down 11.26% from the prior year.
- Non-Current Assets steadied at $19500.0 in Q1 2026 per RLMD's latest filing, from $19500.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $53625.0 in Q2 2024 and bottomed at $16095.0 in Q3 2022.
- Historically, Non-Current Assets has averaged $30613.6 across 5 years, with a median of $28293.0 in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 68.88% — and 2023, when it soared 196.46%.
- Relmada Therapeutics' Non-Current Assets stood at $34875.0 in 2022, then increased by 23.66% to $43125.0 in 2023, then plunged by 49.04% to $21975.0 in 2024, then slipped by 11.26% to $19500.0 in 2025, then changed by 0.0% to $19500.0 in 2026.
- Business Quant data shows RLMD's Non-Current Assets at $19500.0 in Q1 2026, $19500.0 in Q4 2025, and $21975.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | 19,500.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19,500.00 |
| Mar 31, 2026 | 19,500.00 |
| Dec 31, 2025 | 19,500.00 |
| Sep 30, 2025 | 21,975.00 |
| Jun 30, 2025 | 21,975.00 |
| Mar 31, 2025 | 21,975.00 |
| Dec 31, 2024 | 21,975.00 |
| Sep 30, 2024 | 21,975.00 |
| Jun 30, 2024 | 53,625.00 |
| Mar 31, 2024 | 43,125.00 |
| Dec 31, 2023 | 43,125.00 |
| Sep 30, 2023 | 47,715.00 |
| Jun 30, 2023 | 34,590.00 |
| Mar 31, 2023 | 34,875.00 |
| Dec 31, 2022 | 34,875.00 |
| Sep 30, 2022 | 16,095.00 |
| Jun 30, 2022 | 35,238.00 |
| Mar 31, 2022 | 28,293.00 |
| Dec 31, 2021 | 28,293.00 |
| Sep 30, 2021 | 47,275.00 |